JP2024516795A - エベロリムスおよびアムセネストラントを含む組合せ物 - Google Patents

エベロリムスおよびアムセネストラントを含む組合せ物 Download PDF

Info

Publication number
JP2024516795A
JP2024516795A JP2023562510A JP2023562510A JP2024516795A JP 2024516795 A JP2024516795 A JP 2024516795A JP 2023562510 A JP2023562510 A JP 2023562510A JP 2023562510 A JP2023562510 A JP 2023562510A JP 2024516795 A JP2024516795 A JP 2024516795A
Authority
JP
Japan
Prior art keywords
everolimus
amsenestrant
pharma
cancer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516795A5 (enExample
Inventor
モンシフ・ブアブラ
ファンシィェン・サン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024516795A publication Critical patent/JP2024516795A/ja
Publication of JP2024516795A5 publication Critical patent/JP2024516795A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023562510A 2021-04-12 2022-04-12 エベロリムスおよびアムセネストラントを含む組合せ物 Pending JP2024516795A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21315063 2021-04-12
EP21315063.4 2021-04-12
PCT/EP2022/059704 WO2022218958A1 (en) 2021-04-12 2022-04-12 Combination comprising everolimus and amcenestrant

Publications (2)

Publication Number Publication Date
JP2024516795A true JP2024516795A (ja) 2024-04-17
JP2024516795A5 JP2024516795A5 (enExample) 2025-04-16

Family

ID=75825773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562510A Pending JP2024516795A (ja) 2021-04-12 2022-04-12 エベロリムスおよびアムセネストラントを含む組合せ物

Country Status (8)

Country Link
US (1) US20240197692A1 (enExample)
EP (1) EP4322942B1 (enExample)
JP (1) JP2024516795A (enExample)
CN (1) CN117177743A (enExample)
AR (1) AR125330A1 (enExample)
ES (1) ES3036485T3 (enExample)
TW (1) TW202304424A (enExample)
WO (1) WO2022218958A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528246A (ja) * 2013-08-14 2016-09-15 ノバルティス アーゲー がんの治療のための組合せ療法
JP2018537406A (ja) * 2016-02-15 2018-12-20 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2019020559A1 (en) * 2017-07-24 2019-01-31 Sanofi COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528246A (ja) * 2013-08-14 2016-09-15 ノバルティス アーゲー がんの治療のための組合せ療法
JP2018537406A (ja) * 2016-02-15 2018-12-20 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2019020559A1 (en) * 2017-07-24 2019-01-31 Sanofi COMBINATION COMPRISING PALBOCICLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] OXYPHENYL] -8,9-DIHYDRO ACID -7H-BENZO [7] ANNULENE-2-CARBOXYLIC AND ITS USE FOR THE TREATMENT OF CANCER

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BESRET, LAURENT ET AL.: "Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and e", EJNMMI RESEARCH, vol. 10, no. 1, JPN6026016717, 2020, pages 1 - 13, ISSN: 0005856107 *
MASSARWEH, SULEIMAN ET AL.: "A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen recepto", BREAST CANCER RESEARCH AND TREATMENT, vol. 143, no. 2, JPN6026016718, 2013, pages 325 - 332, ISSN: 0005856108 *
増田 慎三: "エベロリムス", 内分泌甲状腺外会誌, vol. 32, no. 2, JPN6026016716, 2015, pages 80 - 85, ISSN: 0005856106 *

Also Published As

Publication number Publication date
CN117177743A (zh) 2023-12-05
EP4322942B1 (en) 2025-04-30
EP4322942A1 (en) 2024-02-21
TW202304424A (zh) 2023-02-01
AR125330A1 (es) 2023-07-05
ES3036485T3 (en) 2025-09-19
US20240197692A1 (en) 2024-06-20
WO2022218958A1 (en) 2022-10-20
EP4322942C0 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
EP4322942B1 (en) Combination comprising everolimus and amcenestrant
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2024516363A (ja) リボシクリブ及びアムセネストラントを含む組み合わせ
JP2023550149A (ja) アベマシクリブと６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸とを含む組み合わせ
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
US20240398809A1 (en) Treatment of alopecia areata
EP3685831A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
CN120302974A (zh) 喹诺林化合物治疗甲状腺癌的用途
HK1257770B (en) Treatment of alopecia areata
JP2018104292A (ja) マグネシウム化合物を有効成分とする医薬組成物

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512